Sun Pharma licenses lerodalcibep from LIB Therapeutics for markets outside the US and China
Sun Pharma has secured rights to commercialise and manufacture LIB Therapeutics' PCSK9 inhibitor lerodalcibep across markets outside the US and China.
The agreement covers the EU-approved therapy, marketed as Lyrokaul, and includes upfront and milestone payments to LIB Therapeutics as well as royalties on future sales.
The partnership expands Sun Pharma's cardiovascular portfolio while providing LIB Therapeutics with a commercialisation partner across a broad international territory.
Field | Content |
Alert Type | Licensing agreement |
Companies | Sun Pharmaceutical Industries; LIB Therapeutics |
Deal Type | Exclusive licensing, commercialisation and manufacturing agreement |
Asset or Company | Lerodalcibep (Lyrokaul) |
Therapy Area(s) | Cardiovascular disease; hypercholesterolaemia |
Technology or Modality | PCSK9 inhibitor |
Deal Value | Upfront and milestone payments plus royalties; financial amounts not disclosed |
Development Stage | Approved in the European Union |
Geography | Markets outside the US and China |
What Happened | Sun Pharma entered an agreement with LIB Therapeutics for the licensing, commercialisation and manufacturing of lerodalcibep outside the US and China. |
Why It Matters | The transaction gives Sun Pharma access to an approved PCSK9-targeted cardiovascular therapy across a broad international territory. |
Supporting Context | Lerodalcibep, marketed as Lyrokaul, has received European Union approval for the treatment of adults with primary hypercholesterolaemia and mixed dyslipidaemia. |
Strategic Rationale | The agreement expands Sun Pharma's specialty cardiovascular portfolio while providing LIB Therapeutics with commercial and manufacturing capabilities across international markets. |
Potential Impact | The partnership could broaden commercial access to lerodalcibep across markets covered by the agreement. |
Key Takeaway | Sun Pharma has secured broad ex-US and ex-China rights to LIB Therapeutics' approved PCSK9 inhibitor lerodalcibep. |
What to Watch | Commercial rollout of lerodalcibep in markets covered by the agreement and any subsequent regulatory or reimbursement developments. |
Primary Source | Sun Pharmaceutical Industries |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires